Immutep to Present at 2018 ASCO Annual Meeting

SYDNEY, Australia, May 04, 2018 -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) (Immutep or the Company) today announced that it will present posters during the 2018 American Society for Clinical Oncology (ASCO) Annual Meeting, being held 1-5, June 2018 in Chicago, Illinois.

Details of the poster presentations in relation to Immutep’s lead product candidate, eftilagimod alpha (also known as IMP321) are as follows:

Abstract Number and Title: 1050, “Combination of paclitaxel and a LAG-3 fusion protein (eftilagimod alpha), as a first-line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): Final results from the run-in phase of a placebo-controlled randomized phase II.”
Poster Session: Breast Cancer—Metastatic
Session Data and Time: Saturday, Jun 2, 8:00 - 11:30 a.m. CDT
Location: Hall A, Poster Board Number: #131

Abstract Number and Title: TPS1109, “AIPAC (Active Immunotherapy PAClitaxel): A randomized, double blind, placebo controlled, multinational phase IIb trial evaluating the efficacy of eftilagimod alpha (a soluble LAG-3 fusion protein) in combination with paclitaxel in hormone receptor positive metastatic breast cancer.”
Poster Session: Breast Cancer—Metastatic
Session Data and Time: Saturday, Jun 2, 8:00 - 11:30 a.m. CDT
Location: Hall A, Poster Number: #185b

Abstract Number and Title: TPS3129, “The "INSIGHT" trial: An explorative, open-labeled phase I study to evaluate the feasibility and safety of intra-tumoral, intra-peritoneal, and subcutaneous injections with IMP321 (LAG-3Ig fusion protein) for advanced stage solid tumor entities.”
Poster Session: Developmental Therapeutics—Immunotherapy
Session Data and Time: Monday, Jun 4, 8:00 - 11:30 a.m. CDT
Location: Hall A, Poster Board Number: #329a

About the AIPAC clinical trial

The ongoing AIPAC (Active Immunotherapy PAClitaxel) Phase IIb clinical trial is a European multi-centre study evaluating eftilagimod alpha (“efti” or “IMP321”) in combination with paclitaxel in metastatic breast cancer (clinicaltrials.gov identifier NCT 02614833). To date, 33 out of a planned 34 clinical sites across Belgium, the Netherlands, Poland, Hungary, United Kingdom, France and Germany are now actively recruiting and treating patients. The study is expected to be fully recruited with 226 patients in third quarter of calendar 2018; first Progression Free Survival data are expected in calendar 2019.

About the INSIGHT clinical trial

The on-going INSIGHT Phase I clinical trial is an investigator initiated, explorative, single centre, open-label, study evaluating the feasibility and safety of intra-tumoural, intra-peritoneal, and subcutaneous injections of efti for advanced stage solid tumour entities (clinicaltrials.gov identifier NCT03252938). The Lead Investigator of this clinical trial is Professor Doctor Salah-Eddin Al-Batran, the Medical Director of the IKF.

About Immutep

Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the U.S.
For further information please visit www.immutep.com or contact:

U.S. Investors:
Jay Campbell, Vice President of Business Development and Investor Relations, Immutep Limited
+1 (917) 860-9404; [email protected]

Australian Investors/Media:
Matthew Gregorowski, Citadel-MAGNUS
+61 2 8234 0105; [email protected]